(HealthDay)—Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care.
Jul 23, 2018
0
0
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH). Now a study has found that empagliflozin, a newer ...
Mar 19, 2018
0
64
(HealthDay)—The reduction in risk of cardiovascular (CV) death with empagliflozin is most mediated by changes in hematocrit and hemoglobin, according to research published online Dec. 4 in Diabetes Care.
Dec 26, 2017
0
6
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research in the journal Diabetes Therapy finds.
Jun 14, 2017
0
0
(HealthDay)—For patients with type 2 diabetes at high cardiovascular risk, empagliflozin is associated with a reduction in incident or worsening nephropathy, according to a study published online June 14 in the New England ...
Jun 15, 2016
0
0
Empagliflozin (trade name: Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. In 2014, the German Institute for ...
Jun 3, 2016
0
1
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and ...
Nov 19, 2014
0
0
